# Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

> **NCT02058641** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 9 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** Darapladib

## Key facts

- **NCT ID:** NCT02058641
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-26
- **Primary completion:** 2014-08-18
- **Final completion:** 2014-08-18
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058641, "Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02058641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*